{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:54:20Z","timestamp":1792043660248,"version":"4.4.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Patients with metastatic castration\u2013resistant prostate cancer (mCRPC) harboring BRCA1\/2<\/jats:italic> alterations are eligible to receive poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors as single agents or in combination with an androgen receptor pathway inhibitor after these agents showed survival improvement in their landmark clinical trials. However, data are limited regarding the uptake of PARP inhibitors in these patients.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the use of PARP inhibitors in patients with mCRPC harboring BRCA1\/2<\/jats:italic> alterations.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study used the deidentified Flatiron-Health electronic health record\u2013derived database of US community and academic practices to extract patient-level data. The data cutoff date was May 31, 2024. Patients with mCRPC with evidence of harboring BRCA1\/2<\/jats:italic> alterations and alive after August 15, 2020 (ie, 3 months after the approval of the first PARP inhibitor, rucaparib, in mCRPC) were included. Statistical analysis was performed from September 2024 to May 2025.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Age, race and ethnicity, insurance status, and practice type at the time of mCRPC diagnosis.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The receipt of PARP inhibitors. Multivariable logistic regression was conducted to assess the association between the exposures and the main outcome.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 24\u202f105 patients with metastatic prostate cancer, 443 male patients (median [IQR] age, 72 [65-79] years) had mCRPC with BRCA1\/2<\/jats:italic> alterations and were eligible and included in our analysis. Of these patients, 227 (51.2%) received a PARP inhibitor, whereas 216 (48.8%) did not. Compared with patients covered by a commercial health plan, those covered by Medicare were significantly more likely to receive a PARP inhibitor (odds ratio, 1.91; 95% CI, 1.02-3.66; P<\/jats:italic>\u2009=\u2009.047). The odds of receiving a PARP inhibitor were not significantly higher in patients treated in community practice compared with those treated in academic centers (odds ratio, 1.64; 95% CI, 1.00-2.70; P<\/jats:italic>\u2009=\u2009.05).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This retrospective cohort study of patients with mCRPC and evidence of BRCA1\/2<\/jats:italic> alterations found that approximately half of patients did not receive PARP inhibitors despite evidence of survival improvement in this population. These findings highlight the need to increase awareness of the survival data and access to life-prolonging therapies in patients with mCRPC.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.34968","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:31:36Z","timestamp":1759419096000},"page":"e2534968","source":"Crossref","is-referenced-by-count":3,"title":["Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1\/2<\/i> Alterations"],"prefix":"10.1001","volume":"8","author":[{"given":"Micah","family":"Ostrowski","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonjung","family":"Jo","sequence":"additional","affiliation":[{"name":"Cancer Biostatistics, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Hage Chehade","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Irem","family":"Ozay","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Gebrael","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sayegh","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayana","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Gordhamer","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ji","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Westwood"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Mathew Thomas","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumati","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irbaz Bin","family":"Riaz","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Maughan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyajit","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, UH Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umang","family":"Swami","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"zoi250978r1","doi-asserted-by":"publisher","author":"Hage Chehade","journal-title":"CA Cancer J Clin","DOI":"10.3322\/caac.21870"},{"issue":"14","key":"zoi250978r2","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi250978r3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann Oncol"},{"key":"zoi250978r4","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer.","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"issue":"18","key":"zoi250978r5","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer.","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10398","key":"zoi250978r6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"22","key":"zoi250978r7","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer.","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi250978r8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer.","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi250978r9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US Food and Drug Administration pooled analysis.","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9596","key":"zoi250978r10","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"24","key":"zoi250978r13","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer.","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"10502","key":"zoi250978r14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet"},{"issue":"10502","key":"zoi250978r15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"zoi250978r16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1200\/JCO.2024.42.4_suppl.54","article-title":"Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.","volume":"42","author":"Benjamin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi250978r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.34208","article-title":"Biomarker-directed therapy in Black and White men with metastatic castration-resistant prostate cancer.","volume":"6","author":"Hwang","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi250978r18","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1136\/ijgc-2024-005599","article-title":"Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare.","volume":"34","author":"Knisely","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"zoi250978r11","unstructured":"Database Characterization Guide. Accessed May 8, 2025. https:\/\/flatiron.com\/database-characterization"},{"key":"zoi250978r12","unstructured":"R Core Team R. A language and environment for statistical computing. R Foundation for Statistical Computing. Accessed August 13, 2025. https:\/\/www.R-project.org\/"},{"key":"zoi250978r19","unstructured":"ClinicalTrials.gov. Study of talazoparib with enzalutamide in men with DDR gene mutated mCSPC. NCT04821622. Accessed August 13, 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04821622"},{"key":"zoi250978r20","unstructured":"ClinicalTrials.gov. A study of niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone for the treatment of participants with deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC) (AMPLITUDE). Accessed August 13, 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04497844"},{"key":"zoi250978r21","unstructured":"ClinicalTrials.gov. Study of AZD5305 when given in combination with new hormonal agents in patients with metastatic prostate cancer (PETRANHA). Accessed August 13, 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05367440"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2839543\/ostrowski_2025_oi_250978_1758815528.84939.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:31:39Z","timestamp":1759419099000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2839543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.34968","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}